Published on
13:12 GMT
FDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatment
Imunon has announced the alignment of the US Food and Drug Administration (FDA) with the Phase III OVATION 3 trial of IMNN-001 for ovarian cancer protocol. IMNN-001, the company’s lead candidate, is being developed for treating women with newly diagnosed …
Source:
Clinical Trials Arena
-
Label Pending
